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REPORT
ON THE REVIEW OF
DIRECTIVE 90/220/EEC
IN THE CONTEXT OF THE COMMISSION'
COMMUNICATION ON BIOTECHNOLOGY
AND THE WHITE PAPER
(presented by the Commission)INTRODUCTION
In the European Union the safety of activities involving modern biotechnology is
currently ensured through four horizontal Directives (Directives 90/219/EEC,
90/220/EEC, 90/679/EEC and 94/55/EC) and a number of other sectoral
Directives/Regulations (see Annex I).
. While Directive 90/219!EEC covers the contained use (i. e. use in research and
industrial facilities) of genetically modified micro-organisms (GMMs), Directive
90/220/EEC covers the deliberate release into the environment of genetically
modified organisms (GMOs). The latter covers both deliberate releases for
experimental purposes, and deliberate releases for placing on the market of
products. Directive 90/220 already foresees, in its article 10(2), that product
legislation could replace the environmental .risk assessment provided. for by Part
C of this Directive. This approach, known as "one door; one key" policy, aims at
ensuring that one assessment and notification procedure are sufficient for the
purposes of marketing products containing or .consisting of GMOs. Under this
policy, products containing or consisting of GMOs will be subject to specific
product legislation, which will include a risk assessment similar to the one
provided for by Directive 90/220/EEC, while being specific with regard to the
intended use of product. Annexes I and II of this Report contain a list of
Community legislation, adopted or under development, relevant for the purposes
of the "one door, one key" policy.
In its Communication on Biotechnology and the White Paper on Growth
Competitiveness and Employment (June 1994), the Commission recognises the
importance of modern biotechnology, and confirms that "in the future the whole
network of interrelated biotechnological regulations needs to ensure that oversight
is always appropriate to the risks involved, the building of public confidence and
to the competitive development of the industries involved while guaranteeing the
protection of human health and the environment. 
1 "On this basis, the Commission
confirmed its opinion" that the following two-track approach for the future
development of the biotechnological regulatory framework should be applied:
the exploitation of existing possibilities for revising
measures/procedures/degree of oversight/requirements, through use of the
light" procedure of adaptation to technical progress (Regulatory
Committee Procedure). (Internal amendment); 
the bringing forward of amendments to existing legislation in order to
incorporate changes which cannot be achieved by technical adaptation
while leaving the basic structure of the framework intact (external
amendment)"l
Biotechnology and the White Paper on Growth, Competitiveness and Employment
preparing the next stage. Communication from the Commission to the Council, the
European Parliament and the Economic and Social Committee, p. 3As far as Directive 90/220/EEC was concerned, the Communication concluded
that this "Directive was flexible enough to satisfy the needs of the time for
adaptation to technical progress and simplifi.cation of the procedures " but it
concluded that "there were aspects of this Directive that might be improved in the
future. 2"
It is in this context that the Commission undertook to carry out a review of
Directive 90/220/EEC with the aim of assessing the need for proposals in relation
to the following objectives outlined in the Communication:
extending the flexibility. of Directive 90/220IEEC, so that its scope and the
procedures to be followed are always appropri~te to the risks involved, and
are easily adaptable;
' .
strengthening more uniform decision-taking between Member States in the
case of research and development releases; 
introducing further opportunities for notifiers (industry and researchers),
so that they can benefit more from the existence of a uniform community
system;
facilitating the link between this Directive and product legislation. 
,,3
Experience gained since the implementation of the Directive, has led to a better
understanding of its functioning. In particular discussions with the Competent
Authorities under this Directive as well as with interested parties has helped to
identify problems and possible ways of addressing them. This experience was not
sufficient to carry out a review of Directive 90/220/EEC during the first half of
1995 as foreseen in the Commission s Communication on Biotechnology and the
White Paper on Growth, Competitiveness and Employment?
This document pr.esents the results. of the review exercise which includes
consultations with the Competent Authorities of Member States, Industrial and
Research Associations, Environmental, Consumer and Trade Union Organisations.
This Analysis carried out below has taken into account international experience in this field. 
Biotechnology and the White Paper on Growth, Competitiveness and Employment
. preparing the next stage. Communication from the Commission to the Council, the
European Parliament and the Economic and Social Committee, p. 5
Biotechnology and the White Paper on Growth, Competitiveness and Employment
preparing the next stage. Communication from the Commission to the Council, the
European Parliament and the Economic and Social Committee, p. 6. ,
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Directive 90/220/EEC came into force on 23 October 1991. Since then 747
experimental releases have been notified.. to Member Sutes Authorities and 16
product notifications have been submitted so far (see Pmnex III). Although this
might look impressive, it has to be seen in perspective of international experience
elsewhere (see annexe IV.
Part A of Directive 90/2201EEC: Genel11J Provisions
Part A of Directive 90/220/EEC mainly defines:
the scope of this legal instrument More specifically:
the circum$~ces under which Directive 90/220/EEC applies
(Article 1 and' definitions for the terms "deliberate release
product", " placing on the market"
, 1I\lS(~
1I provided in Article 2);
organisms to which Directive 90/220/EEC applies (Article 2:
definitions of"organisro" and "OMO", /-\rticle 3 exemptions);
the obligations of Member States.
Regarding part  the analysis carried out has identified the followirig points:
Experience shows that some of the defInitions in article 2 ' in particular
those of "placing on the market" and "deliber.ate release , cause some
implementation problems.
More recently, it has been suggested that Artide 1 paragraph 1 second
indent, which is closely linked. to the definition of "deliberate release
does not indicate unequivocally the circumstan.ees under which products
fall under Directive 90/220IEEC. The pragmati(: approach. followed so far
should be adapted to address the issue, whichinvolvesd a caseMby-case
examination.
Although the whole Directive i!ii supposed to bt: concerned with the
assessment of risks for human and the envirOmC1eD.t, the risks covered and
the criteria for such a risk assessment are not Bpecified. It is to be noted
that product legislation (pharmaceuticals, foc,ds, etc.) has traditionally
defined the objectives of the assessments to be performed under it. It is
hence necessary to incorporate these objectivlt:s in the Directive and. in
product legislatio~ . in order to strengthen hannonisation and to avoid that
authorities of Member States reach different 
(:onclusions on the basis of
the same information.Furthermore, the principle of a scientific risk/benefit,evaluation needs to'
be introduced in order to clarify which side - effects of certain types of
releases would be acceptable, thus allowing authorities to establish the
overall beneficial effect or the release.
Part B of Directive 90/220/EEC: Deliberate release of GMOs into the
environment for research and development purposes or for any other purpose
than for placing on the market
Part B of Directive 90/220/EEC defines the procedure that has to be followed in
the case of experimental release into the environment of GMOs (i. e. submission
of a notification; potential data requirements, risk evaluation, exchange of
oonnnentslinformation between Member States, granting of consent by the
competent authority).
Risk categories and administrative procedures
At the time of the adoption -of Directive 90/2201EEC there had been very
little experience, and it was considered, that all GMO releases would
potentially present similar risks. Against this background one
administrative procedure for research and development releases was
foreseen. The procedure has helped .Member State Authorities to establish
the infrastructure for overseeing this fast-moving sector, and has built
confidence in the public that there is an instrument available to address
risk issues.
However, the experience gained on the basis of practices already
implemented at industrial level indicates that, while keeping a case-by-
case approach, it is necessary to establish a classification commensurate
with the identified risks involved in the release. Indeed, it is currently
demonstrated that not all releases pose the same level of risk and
consequently, do not merit the same level of administrative oversight.
Such classification would allow to lay down administrative requirements
that are in all cases proportionate to the risk identified, thereby eliminating
unjustified administrative burden without lowering safety standards.
The current Directive does not allow for any classification of risk and for
differentiation of administrative requirements according to the risks
involved, Such a classification should be introduced and the administrative
procedures commensurate to the risks involved. This approach has been
already applied elsewhere in the world.
Simplified procedures
The Directive foresees the possibility to adopt simplified procedures
(Article 6. ), in cases where certain criteria are met. This possibly has
only been used once, in order to allow for a single notification to cover
the release of a combination of specific genetically modified plants on
different sites. Although it is true that the possibilities for simplified
procedures may not have been fully exploited, the pr~sent situationillustrates the shortcomings of the possibilities for simplification 
currently foreseen by the Directive:
The fact that only one simplified procedure has been so far adopted
demonstrates that the procedure for proposing and adopting them
is cumbersome, and certainly does not meet the need for rapid
adaptation in the biotechnology field.
these simplified procedure catinot replace the need for a clet.. ~u~
well defined classification system linked to the risk involved.
Furthermore the possibility for proposal of simplified procedure
should be extended to all parties involved.
Multi-State procedures
Directive 90/220/EEC does not provide for the possibility of a single
procedure for multi-State releases. As the field develops it becomes more
and more necessary to test GMOs in more than one Member State. Such
a procedure would be especially advantageous for SMEs, which are
usually not based in more than one Member State. 
It is therefore necessary to have such a provision introduced.
Risk assessment
At the time of adoption ofthe Directive it was not possible to specify the
basis of the risk assessment, that has to be carried out, (see .above) or the
methodology to be followed and the safety standards that have to be
satisfied in the text of the Directive. Although the system of the Directive
works even in the absence of commonly accepted objectives and
methodology, it has to some degree led to lack of harmonization in safety
standards in Member States. Consequently, a notifier has to comply with
different requirements when releasing in different Member States.
With the accumulated knowledge and experience it is now possible and
necessary to establish centralised definition of the objectives and
methodology of the risk assessment.
Exchange of information between Member States
Article 9 specifies that exchange of information on experimental releases
should take place. This is already happening, and the Commission intends
to set up a database. Experience gained with over 700 experimental
releases notified to Member State authorities shows that it would be useful
for the Commission to receive appropriate information concerning the
subsequent approval of products in order to circulate this to Member
States. This would enable Member States to have information about
assessment on safety of products and more specifically the results of the
releases.Therefore strengthened provisions on the issue of exchange of information
between Member States should be introduced.
Link between experimental and product releases
The Directive foresees that experimental releases ofGMOs should pose no
risk to human health and the environment under the purpose or conditions
in accordance with Article 6. It could be explored how the experience
gained under part B could be used for possible environmental problems
that could arise at the stage of commercialisation. This could be done by
collecting information or data to address them. (See paragraph e) above.
Tl1erefore, the possibility could be explored of introducing in the
Directive an incentive or an obligation to gather data/information which
could be of relev(i.nce to the subsequent evaluation of the. GMO in view
of its placing on the market as product under part C of Directive
90/220/EEC or under the relevant product legislation, as appropriate.
It is worth underlining that in the case of placing on the market of GMOs
Community legislation on products currently discussed in the Council and
the Parliament does not foresee a specific environmental risk assessment
for research and experimental releases of GMOs and refers to
authorisations that have been given to part B releases under Directive
90/220/EEC". Therefore, it could be useful that the assessment of the
environmental effects of GMOs to be placed on the market, be prepared
and, if possible, be completed at the research and development stage
under Directive 90/220/EEC. Therefore, in certain cases the possibility
should be explored of including into product legislation which already
foresees an environmental and human health assessment for experimental
releases of products under development, a risk assessment similar to that
laid down in part B of Directive 90/220/EEC.
Part C of Directive 90/220IEEC: Placing on the market of products
containing GMOs
Part C of Directive 90/220/EEC defines the procedure to be followed in the case
of the placing on the market of products containing or consisting of GMOs. This
procedure involves the submission of a notification to a competent authority of
the choice of the notifier, and in the case of a favourable opinion by this
authority, involvement of all the other authorities and possibility to raise
objections within a set deadline. in the case of an objection being raised the
- Commission has to table a proposal for a decision.
Risk categorisation and administrative procedures
Since the entry into force of the Directive, 16 applications for placing on
the market of products containing or consisting of GMOs have been
submitted under this Directive. The administrative procedure which the
Directive foresaw as the general rule (marketing possible after the 90-days
period during which CAs may comment) has not been used a single time.In one case, it has even be necessary for thy Commission to submit to the
Council a proposal for a Council decision (Maize). So far the assessment
carried out by one Competent Authority to which the notification was
submitted, has not been able to satis~y all. other Competent Authorities
which again carry out t.heir own assessment, often on the basis of different
criteria (see analysis concerning part A). It should also be noted, that
although deadlines are given to Member States for examining the dossiers
and pronouncing their opinion, no deadlines are given to the Commission
despite its crucial role in the granting of consents for products. Experience
has shown that the procedure followed is difficult to implement, time-
consuming, and cumbersome to follow both for users and authorities.
Furthermore, the Directive foresees only one procedure whicb is
indistinctly applied to all types of products, irrespective of the risk
identified or whether similar products are already on the market. It has to
be remembered that in this fast-moving, high-tech field, not only future
notifications but also current ones already concern products which are
similar to authorised ones in the EU, as well as products which themselves
have been used elsewhere in the world and which have proven to be safe.
There is therefore a need to provide for streamlined procedures for those
products posing no, negligible or low risk. Such a possibility exists
elsewhere in the world. For example, there are GMOs - with which
familiarity exists (along the lines of the concept of familiarity as defined
within OECD work, especially for the assessment of genetically modified
crop plants).
The establishment of categories according to the risk identified, the
streamlining of administrative procedures in those cases where no
negligible or low risk is involved, without lowering the safety level, should
be introduced. In the same time, the Commission should consider an
adaptation of its internal rules in order to speed its stage of the procedure.
It should also be noted that the current procedure according to which
notifiers have no other option but to submit a new notification to another
Member State in case of an unfavourableopinion by the authorities to
whic~ they had first submitted the notification, is disadvantageous for
SMEs as they are not based in more than one country.
Risk assessment and scientific advice
The lack of a common definition of the objectives and the methodology
of the risk assessment (see analysis concerning part B) allows Member
States to carry out a risk assessment on the basis of different criteria. This
is one reason for the delivery of diverging opinions and the difficulty in
reaching consensus among Member States.
These questions, have to be further clarified in particular, by including,
along the lines of what is proposed for Part B, a clear definition of the
objectives and methodology of the risk assessment.In any case, and in view of the fact that in the future the environmental
assessment for many. products currently covered by part C of Directive
90/220/EEC, will be carried out under appropriate sectoral legislation
(where it exists), it is of utmost importance that the objectives of the risk
assessment be clearly defined for the following reasons:
sectoral Community legislation will foresee an environmental risk
assessment "similar to that foreseen by Directive 90/220/EEC" (i.
without lowering safety standards). If the objectives of this
assessment is not clarified enough in Directive 90/220/EEC . the
current problems concerning the assessment of risks of GMOs will
be transferred to sectoral legislation;
ii) well defined objectives in Directive 90/220/EEC will ensure that
the risk assessment is carried out on the same basis throughout all
stages of the dev~lopment of a product containing GMOs.
Currently, the Directive does not provide the possibility to discuss, at
Community level, scientific controversy within an independent scientific
group, as it is the case in Community. legislation dealing with marketing
authorisations (foods. pharmaceuticals. feed. etc. . This leads to an
anomalous situation where application controversy cannot be dealt with by
an independent system of conflict resolution which would allow to discuss
and solve problems on a scientific basis. This specific issue merits to be
specifically considered in the context of developing a proposal for
amendment to the Directive.
Labelling
The issue of labelling of products under Directive 90/220/EEC has been
the subject of controversy. Some Member State Authorities object to the
placing on the market of a product whose labelling will not indicate that
it is genetically modified. The current provisions of the Directive do not
allow the imposition of such labelling in the absence of any link to risk
assessment. Specific provisions on labelling are; however, foreseen in
product legislation.
It will be essential to address this issue in order to take into account the
need to inform consumers and to comply with the international obligations
of the Community. The issue of labelling will be considered when
preparing the amendment of Directive 90/220/EEC and the final provisions
of other relevant product legislation will be taken into account.Part D and Annexes of Directive 90/220/EEC:
The flexibility of the Directive appears to be limited as it does not provide for
easy adaptation to technical progress of one of its Technical Annexes. In a so fast-
moving and continually evolving field, it is important to ensure that CoJl1munity
provisions are always based on the latest stage of experience and scientific
knowledge. Therefore, the possibility of adapting all annexes of the Directive
though a Regulatory Committee Procedure, could enhance flexibility and permit
timely adaptation of these highly technical parts of the Directive to rapidly
advancing scientific and technical progress.
CONCLUSIONS
Directive 90/220/EEC regulates a high-technology field, which is developing
rapidly. The Directive covers both the stages of development and placing on the
market of products containing  GMOs.  In this light, there is a need for regular
updating and adaptation of this Directive in order to keep pace with scientific and
technological progress.
Directive 90/220/EEC has helped Member States to introduce the infrastructure
for assessing potential human health and environmental effects from the placing
on the market of products containing GMOs, but its implementation has revealed
a nu~ber of problem areas. These include
insufficient clarification concerning the objectives for risk assessment
which has hindered full harmonisation between Member States at the
research and development stages and which has led to disagreements
between Member States at the stage of placing on the market of products;
absence of a risk classification as well as of a link: between administrative
procedures and identified risk, which may result in cumbersome
procedures for low risk releases;
weak link between parts Band C  of  the Directive, which means that
experimental releases under part B do not always provide the relevant
data for the environmental assessment necessary for the placing on the
market underpart C;
cumbersome administrative procedures and approval system for placing on
the market of products, which have led to delays in approving products;
absence of an active role for the Commission on a number of aspects
including the right to propose simplified procedures and to acknowledge
part C dossiers and objections, which has led to delays in exploiting
existing possibilities for simplification and to problems in implementing
part C;
absence of a possibility to resolve controversy through consultation of
independent Scientific Committee(s), which has caused problems in
implementing part C;
absence of sufficient flexibility for technical adaptation, which prevents
regular updating of the Directive to scientific and technical progress;
current labelling requirements.Rccognising the above...mentio1J.ed points aJ:).d the need for a regulatory horizontal
framework sufficiently flexible and specific to ensure  high level of
environmental and human health safety and transparency, while facilitating the
development of this important technology, the Commission intends to adopt in the
course of 1997 a Proposal for an amendment of Directhre 90/220/EEC.
At the same time, while. undergoing the procedure for adopting an amended
Directive, which will involve a co-decision of the Council and the Parliament, the
Commission is co111II1ittedto making full use of all the tools and flexibility of the
current Directive. More specifically the oCommission will
intens~ the wotkof the Risk Assessment Group established in the
framework of the Cotnl11ittee of Competent Authorities, SO thata.common
approach to risk assessment objectives .and metb.odologycanbeadopted
as guidance in March 1997;
encourage and facilitate the submission by Col:apetent Authorities. of a
proposal for simplified procedure allowin.g multi-State experimental
releases ofc~ GMOs to take place under af:ingle consent; 
facilitate through the .preparatio~ of technical documents the
implementation of Directive 9O/220IEEC; .
take a proactive role in the case ofproductnotifif~ationsandencouragethe
exchange of . views between competent authorities much earlier than
. foreseen in the Directive; -
ensure that its internal procedures will be .applif~din .anefficient manner
'ensure thes;peedy adoption of Decisions On l~roducts.AoOex I
HORIZONTAL LEGISLA nON COVERING THE SAFE USE OF MODERN BIOTECHNOLOGY
Directive 90/219/EEC on the contained use of genetically modified micro-
organisms (GMMs).
Directive 90/220/EEC on the deliberate release into the environment of
genetically modified organisms (GMOs).
Directive 90/679/EEC on the protection of workers from the risks related
to exposure of workers to biological agents at work.
Directive 94/55/EC on the transport of dangerous goods by road, where
GMMs are classified as infectious substances for the purposes of transport.
SF.crooAL LE'.GISI.A~ COVERING mE SAFElY OF PRWUCfS OF MDERN :amECHNOLOGY
Council Regulation 93/2309/EEC laying down Community procedures for
the authorisation and supervision of medicinal products for human and
veterinary use and establishing a European Agency for the evaluation of
medicinal products.
Directive 9 1/4 14/EEC  concerning the placing of pI ant protection products
on the market (needs to be amended to incorporate the environmental
safety ofGMO~).
Directive 93/114/EEC amendihg Directive 70/254/EEC concerning
additives in feeding stuffs.
Directive 94/40/EC amending Directive 87/153/EEC fixing guidelines for
the assessment of additives in animal nutrition.Annex II
Sectoral legislation currently at the stage of discussion in the Couhcitand the
Parliament
Proposal fora Cout1cil Regulation concerning novel faods and novel food
ingredients.
Proposal. fot a. Council Directive amending Directives  66/400/EEC.
66/401IEEC.,. 66/4~/EEG, '66/403IEBC, 69/208/EEC, 70/451/EECand
70/458/.eEConth~m..keting orbed seed, fodder plant seed..'~~teatseed
$ee4 po~toe~., see4) of oil $i1d fibre plants and vegetable seed arid on the
~morkc~talogue of varieties of ~lturalplant species.ANNI~X 
GENETICALLY MOOIFIED PRODUCTS PLAcED ON THE MARKET IN EURoPE
ST ATE OF PLAY IN SEYfEMBEB 
A,. A,JprBwd pr~:
p...dPct Notifier Date of Commissioo Bed'"
Vaccine apiD$t Vemie Veterinar Chetnie 18.12. A~ys diIeue. GmbH
VacciJ!re  rabies RbOne-Merieux 19.10.
Tobacoo tolcrmt to SEITA 03.06.
b~XYBi1.
Vacct'*1 Vcntie Veterinar Chemic 18.07.
Altjestky~ 4isease GmbH
(further UIeI)
Oilseed rape resistant to Plant Genetic Systems 06.02.
gl(,tfo~ mmDOBium
SoybGMS tok.'nmt to Monsanto 03.04. gly~
Male sterile oNcory BGjo-Zadcn 20.05.
tolerant to 
.....PENDING APPR(')VALS:
Product and date of receipt by the Commission
Matze tolerant to glufosillate ammonium and expressing CrylA endoLOxin
(15.03.95)
Oilseed rape tolerant to glufosinate ammonium
(20.07.95)
scs: no conditIOns.
Oilseed rape tolerant to glufosinate ammomum (Extension of.previous
Com. DeCISIon to other uses. including ffJod proeessmg)
(20.07:95)
Oilseed rape tolerant to glufosinate ammomum
(03.05.96)
* u
: -
Import or seed fill' processmg:
growing rorbreeding;
field cropping for grain.
Maiz.c tolerant to glufosinatc anmlOnium
(24.05:96)
uses: no conditions
Maiz.c cxpresslIlg CrylA endotoxin
(24.05%)
uses: no conditions
Test kit to detect antibiotic residues In milk *  Streptococcus. thermophilus
with  luxA
and  luxBand  expressed  Celt  gene coding f()r resist. to chloramphenicol
(11.06.96)
lnsl:ct resistant maize
(06,08.96)
uses: no conditions
Male sterile chicory tolerant to glufosinatc ammonium
(20.09.96)
uses: food and feed
Notifier
Oba-(;cigy
Plant Genetic
Systems
Plant Genetic
Systems
A:grEvo
AgrEvo
Monsanto
Valin Oy
Pioneer
Bejo~Zaden
:BVANN":X IV
GENETICALLY Monumm PRODtJCrS PLAn:D ON TIn: MARKKr ourSHn: Oi" EUROI'I':
SI' An': 01" PI , "IN Slwn:1\1IW,
Product Notifier Country giving approval
1.1 Phosphinothricin AgrEvo USA
tolerant soybean
1.2 PR V resIstant Papaya Cornell USA
('MV, WMV2 and Asgrow USA
/,\' MV IcsIS1~UlI sqllash
1.4 Potato resistant Monsanto USA
Colorado potato beetle
1.5 Ripening altered tomato Agritope USA
Sllllbnyllln~a tolnant nil Ponr USA
cotton
Male sterile Plant Genetic Systems USA
phospilinolhrklll
tolerant corn
1.8 Corn resistant to Northrup King USA
European com borer
1.9 Ripening altered tomato Calgene USA
I () Phosphinothricin OeKalb USA
lolnant rom
1.11 Lepidopteran resistant Monsanto USA
com
1.12 R~pening altered tomato Monsanto USA
Glyphosate to Ie ran I  Monsanto USA
cotton
1.14 Phosphinothricin AgrEvo USA
tolerant com
1.15 Lepidopteran resistant Ciba Geigy USA
com
1.16 Lepidopteran resistant Monsanto USA
cotton
Polygalacl\lronasl~ level Zcncca & Pctosccd USA
dccn;asl~d lomatoProduct Notifier Country giving approval
nkophmm fl~slstallt Mollsanto USA
potato
RIpening altered tomato DNA 1'1~U11 Tech USA
. - ... . . . ...  ...
2!) Oil profile altered aIgene USA
rc:qJCseed
1.21 Glyphosate tolerant Monsanto USA
soybean
1.22 Br0l11oxynil tolcrant Calgcne USA
cotton
1.23 WMV2 and ZYMV Upjohn USA
rcststantsquash
2.1 tilulosll1atc AgrEvo Canada Inc.
( '
allada
anunomuum tolerant
canola
Rouudup'R) herbicide Mous:U1to C:umdalnc. emMa
tolerant  Brass/cel "aplts
canula IineGT73 f-----
.'3 IlIIllIal.Ol nit HIe lo\cJ;J1I1 PIOneer Ih~Bred Inkmatl(Hlul
( '
;llImla
callola Inc.
Novel hybridization  Plant Genetic Systems Inc. Canada
system for canola
(Brass/ca napus 
2.5 Glyphosate tolerant MonsantoCannada Inc. Canada
soybean
(( 
;~l'('jne max
) line tiTS 4()-
Potato resistant to Nature Mark Potatoes Cannada
Colorado potato beetle
(Solanumtuberosum  L.)
Roundupoo herbicide Monsanto Cannada Inc. Canada
lolenult l/rllss/I'II flOpll.
canula line tiT2()!)
L:mmte rapeseed Calgcnc Inc. anada
(llrm:s/clI tllIlms 
Event 176  B1  com (Lea Ciba Seeds and Mycogcn Canada
mays  L.) Corporation
Imidazolinone tolerant Pioneer Hi-Bred Intemational Canada
com 3751IR Inc.2.11
Product
Glufosinate
ammonnium tolerant
canol a line HCN29
3.1 . HeIbicide tolerant
soybean
HeIbicide tolerant
canola
3.2
3.3 Insect resistant com
developed by Northrup
King
Insect resistant potato
Herbicide tolerant
canota developed by
AgrEvo Canada Inc.
3.4
3.5
Insect resistant com
Herbicide tolerant
canola developed by
PGS
Notifier
AgrEvo Canada Inc.
Monsanto Japan Limited
Monsanto Japan Limited
Monsanto Japan Limited
Monsanto Japan Limited
Hoechst Sheling AgrEvo
Ciba Geigy Japan
Monsanto Japan Limited
Country giving approval
Canada
Japan
Japan
Japan
Japan
Japan
Japan
Japan